Gilead’s chief scientific officer, John McHutchison is to leave the company at the beginning of next month during a period of change at the big US pharma.
Belgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis drugs, where the big US pharma will pay $3.95 billion up front and
The industry is increasingly aware of the importance of corporate social responsibility (CSR) programmes – and Alex Kalomparis, Gilead’s vice president of public affairs for EMEA, says they
ViiV is continuing its assault on arch-rival Gilead in HIV, with phase 3 results aimed at giving doctors confidence that patients can switch from rival triple therapies to its new two-drug
